Melanoma is a heterogeneous tumor with different subpopulations showing different proliferation rates. Slow-cycling cells were previously identified in melanoma, but not fully biologically characterized. Using the label-retention method, we identified a subpopulation of slow-cycling cells, defined as label-retaining cells (LRC), with strong invasive properties. We demonstrate through live imaging that LRC are leaving the primary tumor mass at a very early stage and disseminate to peripheral organs. Through global proteome analyses, we identified the secreted protein SerpinE2/protease nexin-1 as causative for the highly invasive potential of LRC in melanomas.
INTRODUCTION
Melanoma accounts for~4% of all skin cancer cases but for 470% of all skin cancer deaths. Although tumor development and progression, from benign proliferative lesions to dysplasia to overt malignancy, typically follow a stepwise pattern, metastatic dissemination remains difficult to predict and treat because of the heterogeneity in this disease. Heterogeneity manifests both at the genetic and epigenetic/phenotypic levels. Of all human cancers, melanomas have the highest mutational load with hundreds to thousands of mutations per tumor. While the field has identified 20 driver mutations in this disease, [1] [2] [3] [4] [5] [6] [7] [8] [9] the different combinations of driver mutations that are possible make it challenging to identify genetic subgroups for outcome prediction of continuous growth, invasion and dissemination, or, in advanced metastatic disease, immunotherapy or targeted therapy.
Heterogeneity of melanoma is displayed not only between tumors but also within tumors. Differences manifest in growth rates, pigmentation, differentiation states to other cell types, structural cellular elements, matrix formation, or host cellular infiltrates. While most cancers contain unique cell populations generally described as cancer-initiating cells, melanoma does not follow this pattern. Instead, melanomas contain subpopulations whose presence is dynamically regulated by microenvironmental signals. We previously defined a slowly-cycling subpopulation in melanoma that is important for tumor maintenance and drug resistance. This subpopulation, which proliferates at a much slower rate than the main population, was defined by expression of the H3K4 demethylase JARID1B 10 and represents only 0.5 to 5% of all cells. It is regulated by hypoxia, growth factors, and cytokines such as IGF-1 or TNF-α. [10] [11] [12] Expression of the transcription factor microphtalmia-associated transcription factor (MITF) has been used as biomarker to distinguish populations of melanoma cells that are highly proliferative and poorly invasive (MITF High ) or slowly proliferative and highly invasive (MITF Low ). [13] [14] [15] MITF is a master regulator for melanocytes and melanoma cells and essential for the survival of all pigmented cells whereas JARID1B expression characterizes a subpopulation within slow-cycling melanoma cells, since not all the slow-cycling melanoma cells express JARID1B. We focused in the presented experiments on slow-proliferating melanoma cells that included both JARID1Bposive and -negative melanoma cells.
All cells can take up a membrane-staining dye, but after two to three cell divisions the dye is diluted and becomes undetectable by fluorescence microscopy whereas label-retaining cells (LRC) retain the dye for longer periods of time, which defines melanoma slow-cycling cells as biologically LRC. Similar dye-retaining experiments are well described for stem cells with high turnover of the main population. For example, epithelial stem cells in the skin were defined by retention of bromo-deoxy-uridine. 19, 20 Here we characterize the invasive properties of slowly-cycling melanoma cells both in vitro and in vivo. We demonstrate that human melanoma LRC are highly invasive and disseminate more rapidly in immunodeficient mice to lymph nodes, lungs, liver and spleen than non-LRC. After dissemination, significantly larger metastases are observed in LRC-injected mice. We then identified a secreted protein, SerpinE2/Protease nexin-1 (PN-1) or glia-derived nexin, as causative for the highly invasive potential of LRC. SerpinE2 is a member of the Serpin gene superfamily with anti-serine protease activity and acts as major regulator for both tissue-type and urokinase plasminogen activators.
RESULTS

Melanoma LRC are slow-cycling and invasive in vitro
Slow-cycling melanoma cells have been identified by us and others 10, 21, 22 but knowledge of their biological properties has been limited to growth and drug resistance. When cultured cells from human metastatic melanomas are labeled with membrane dyes such as CellTrace Violet (Molecular Probes, Eugene, OR, USA) or PKH26, they dilute the dyes with each cell division. Thus, only non-proliferating or slow-dividing cells retain the label for prolonged periods of time, defining this subpopulation as LRC. In vitro, using CellTrace Violet, LRC were found in all metastatic melanoma cell lines analyzed (Figures 1a and b ). In each cell line this LRC subpopulation emerged after 4 days in culture and could be detected for up to 3 weeks, at which point the membrane dye could no longer be detected due to cell divisions (Figure 1b ; Supplementary Figure 1A) . Their presence was not associated with any genetic subgroups of melanomas such as those representing mutant BRAF, NRAS or BRAF/NRAS wild type. Of all cell surface markers previously used to define melanoma-initiating cells, including CD20, CD271 or CD133 [22] [23] [24] we saw no distinct expression patterns in the LRC populations except that CD20 was upregulated in LRC of 4/8 melanoma cell lines (Supplementary Figure 1B) . Most, but not all, LRC express the H3K4 demethylase JARID1B, 10 which we confirmed at the singlecell level by mRNA fluorescence in situ hybridization (FISH; Figure 1d ). LRC are enriched in G2/M of the cell cycle (Figure 1c ; Supplementary Figure 1C ) and no differences were observed between LRC and non-LRC in S phase (Supplementary Figure 1D ). LRC are highly invasive through basement membrane matrix, Matrigel ® (Corning, Tewksbury, MA, USA), when tested in Boyden chamber assays. Differences in invasiveness varied among cell lines with LRC being 2-to 8-fold more invasive than their respective non-LRC populations (Figure 1e ; Supplementary Table 6 ).
Melanoma LRC exit the primary tumor mass and disseminate in mouse tissues
We then investigated in vivo the growth and invasive dynamics of LRC originally isolated from metastatic lesions. Figure 2a provides a schematic for the experiment, in which we labeled melanoma cells in vitro with the membrane dye PKH26 and injected 10 6 cells subcutaneously into SCID Hairless Outbred (SHO ® ; Charles River Laboratories, Wilmington, MA, USA) mice. PKH26 was chosen because the fluorescence allows scanning of labeled cells by IVIS ® (PerkinElmer, Waltham, MA, USA) in vivo. SHO mice were selected because they are hairless and have thin skin, allowing better scanning of internal organs than other mouse strains with fur. We monitored the mice weekly for fluorescent signals by placing them in dorsal, ventral, and lateral positions to test the hypothesis that the normally proliferating cells at the injection site (primary tumor) would rapidly lose the fluorescent signal, whereas LRC would readily disseminate, retain the signal, and remain visible at a distant site. Indeed, PKH26 was detected in the primary tumors only at the beginning of the experiment and it was diluted when tumors expanded in size (Figures 2b and c) . Demonstrating the consistency of the technique, the PKH26 dilution followed the same kinetics, whether tumors grew faster (451Lu) or slower (WM989). The dye was no longer detectable when tumors reached~500 mm 3 in size.
Over time, as the primary tumor grew, the signal disappeared from it, but appeared at distal locations. Signal was detected in mice injected with WM989 cells and scanned in the ventral (5/5 positive) and lateral (4/5 positive) positions; for 451Lu cells, 2/5 mice were positive when imaged in the ventral position ( Figures 2c and d ). When ND238 cells were injected into 10 mice, 8/10 showed positive signal in their peritoneal cavities ( Supplementary Figure 2A) . Similarly, after injection of WM3942 cells, we detected positive PKH26 signal in 4/4 mice left flank and in 4/4 peritoneal cavities (Supplementary Figure 2B ). Thus in all 4 models analyzed we could observe the same general dissemination LRC. When the primary tumors reached~1000 mm 3 in size, mice were sacrificed and tumors and organs (lungs, liver, spleen and detectable lymph nodes) were harvested and analyzed by flow cytometry for melanoma LRC. Confirming that LRC migrated from the primary tumor, we found that the percentage of LRC (mouse lineage negative, CD146+, PKH26+) was higher in all distal organs compared with the primary tumor (Figure 2e ; Supplementary Figure 2C ). A representative example is shown in the Zebra plots of Figure 2e , with LRC represented by the upper right quadrants. Results were confirmed by immunohistochemistry of tissue sections from lungs and spleen ( Figure 2f ). We were able to monitor LRC in the same location for the same animal for up to 20 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days after the initial detection of signal. These observations indicate that the majority of LRC do not begin proliferation immediately after entering an organ but can remain dormant for extended time periods (Supplementary Figure 2D) .
To directly compare the ability of LRC and non-LRC to disseminate, we sorted LRC from non-LRC and injected s.c. both populations into different recipient mice. Sorted LRC and non-LRC rapidly re-equilibrated their parental redistribution in vitro (Supplementary Figure 3A) . This dynamic is well established for JARID1B (Roesch 2010 ) and we believe it occurs also in vivo. The total metastatic burden (measured as metastatic spots detected by live imaging) was higher for mice injected with LRC than non-LRC (Supplementary Figure 3B ). Representative images of mouse lungs showed larger metastatic areas for those from LRC than those non-LRC (Supplementary Figure 3C ). The ability to regain proliferative capacity of LRC is underscored by the observation that LRC and non-LRC generate primary tumors in recipient mice with comparable growth rates (Supplementary Figure 4A ). Moreover, a majority of cells in LRC-derived xenografts is positive for the Ki67 proliferation marker (Supplementary Figure 4B ). Injection of cells labeled with luciferase, allowed us to image organs at long delayed time point, and these experiments confirming the presence of growing metastatic lesions in distant organs (representative image in Supplementary Figure 5A ).
Proteome analyses reveal upregulation of SerpinE2, PDGFRL and BMP1 in LRC
To understand the invasive phenotype of slowly-proliferating cells, we performed mass spectrometry based comparative and semiquantitative proteomics using tryptic digest of LRC and non-LRC from five different melanoma cell lines by mass spectrometry. From this extensive analysis, we selected for further study proteins preferentially expressed in LRC over non-LRC. Most consistently overexpressed in LRC, across all cell lines, were three proteins, SerpinE2, platelet-derived growth factor receptor-like (PDGFRL) and bone morphogenetic protein 1 (BMP1; Figure 3a ; Supplementary Tables 1-5 ). We validated only SerpinE2 and BMP1 because these proteins were more likely to be relevant for cancer cell aggressiveness (and limited tools were available to study PDGFRL). We confirmed that SerpinE2 and BMP1 are expressed at higher levels in LRC than non-LRC by single-cell mRNA FISH and qRTPCR on LRC and non-LRC total cells (Figure 3b ; Supplementary Figure 6A ) and by immunofluorescence ( Figure 3c ). To ensure that SerpinE2 and BMP1 expression was not an in vitro artifact, we validated expression in primary tumor sites and distal metastatic organs by immunofluorescence and flow cytometry (Figure 3d ; Supplementary Figure 6B ). We additionally observed that human SerpinE2 expression is increased in mouse spleen compared with primary tumors (Supplementary Figure 6C ). We then investigated whether SerpinE2 expression is associated with the slow-cycling phenotype in melanoma and whether it correlated with expression of JARID1B and MITF. SerpinE2 is enriched~6-fold in slow-cycling cells identified as double positive for JARID1B and PKH26 compared with fast proliferating cells (JARID1B-/PKH26-; Supplementary Figure 6D ). At the single-cell level SerpinE2 expression is positively correlated to JARID1B expression in the total LRC and non-LRC fractions (Supplementary Figure 6E ). Conversely, there is no correlation between SerpinE2 and MITF Figure 6F ). This suggests that SerpinE2 and JARID1B are partially overlapping markers and enriched in LRC. Their expression is nevertheless not exclusive for LRC. Non-LRC can express JARID1B and SerpinE2, albeit at significant lower levels. We then focused on SerpinE2 as a candidate for highly invasive LRC. Slow-cycling melanoma cells are highly invasive M Perego et al SerpinE2 is critical for melanoma invasion and its expression level correlates with tumor progression To investigate the role of SerpinE2 in melanoma invasion, we sorted melanoma LRC and non-LRC and performed an invasion assay overnight in the presence of human recombinant SerpinE2. In the presence of exogenous SerpinE2, non-LRC gained the ability to invade, whereas the invasive capacity of LRC was not significantly affected (Figure 4a ; Supplementary Figure 7A ; Supplementary Table 7 ). 25 For validation, we blocked the antiproteolytic activity of SerpinE2 with a specific monoclonal antibody. 26 Neutralization of SerpinE2 reduced melanoma invasion in a dose-dependent manner in all four models tested (Figure 4b; Supplementary Figure 7B ). SerpinE2 knockdown with shRNA ( Supplementary Figure 8 ; Supplementary Table 8 ) also confirmed the inhibition of invasion ( Figure 4c ). Notably, invasion was affected only when successful knockdown was achieved (Sh_13-16), and it was not impaired in the presence of noneffective Sh_17 (Figure 4c ; Supplementary Figure 8 ). For further analyses, we chose Sh_14 and Sh_16, showing most effective knockdown across all cell lines tested ( Supplementary Figure 8 ). SerpinE2 knockdown specifically affected melanoma invasion, without impairing cell proliferation or viability (Supplementary Figure 9 ).
SerpinE2 is nearly absent in supernatants from the five normal melanocyte cultures (MC) tested, but is present in supernatants from all seven melanoma lines tested (WM; Figure 5a ). The 2D finding was confirmed in 3D skin reconstructs, with only melanoma cells staining positive for SerpinE2 ( Figure 5b ). SerpinE2 mRNA expression is absent in normal skin as shown by analysis of a public data set (GEM_1375) and increases with malignant progression (Figure 5c ). Immunohistochemistry analyses on patient tissues confirmed the association between SerpinE2 expression and melanoma progression, with the strongest expression in invasive and tumorigenic vertical growth phase (VGP) primary tumors and metastatic lesions (Figures 5d and e ). Benign lesions (nevi) showed a dotted expression pattern (Figure 5d , arrows) typical of Golgi-associated localization, which switches to extracellular staining in malignant lesions, supporting the involvement of secreted SerpinE2 in invasive progression. Intriguingly, the variability of SerpinE2 expression in VGP reflects the known cellular heterogeneity of this type of lesion, 27, 28 whereas metastatic lesions show more uniform staining, suggesting a possible selection of SerpinE2-high expressing cells during metastasis formation.
DISCUSSION
We describe a subpopulation of human melanoma cells that proliferates much slower than the main tumor population but is highly invasive, both in vitro and in vivo. This subpopulation does not correlate with any genetic signatures of melanoma cells such as the status of BRAF, NRAS or PTEN mutations. We defined this subpopulation as LRC because of the dye-labeling technique used for their identification. After injection into immunodeficient mice, LRC migrate from the primary tumor to distal sites (spleen, lungs and lymph nodes); this migration could be visualized in vivo for 20 days. While proliferation is considered a hallmark of aggressive cancers, we demonstrate here that slow-proliferating cells are more invasive and thus the most dangerous cells (Figures 1 and 2 ; Supplementary Figure 2 ). Our findings are in-line with reports from cultured tumor cells that LRC have increased invasive potential, for example in pancreatic adenocarcinoma, 29 and that non-proliferative, senescent-like melanoma cells can be invasive in vitro. 30, 31 The secreted protein SerpinE2 strongly augments LRC's invasive potential. The identification and characterization of this slowly-proliferating melanoma subpopulation urges us to begin adjusting our treatment strategies of biologically early disease, because we may not detect individual, disseminated tumor cells with current diagnostic techniques.
Invasion and dissemination are the first steps in the metastatic cascade, with many cells able to survive when circulating in the lymph and blood vascular systems, but only a small percentage is able to initiate growth at the new site. Understanding the biological events at the distal sites is critical for being able to prevent or slow metastases. We observed that some LRC in peripheral organs remained detectable for days without any dye lost, i.e., they remained dormant (Supplementary Figure 2D) .
This dynamic resembles clinical patterns, where tumor cells that disseminate early can remain dormant for extended time periods but then (via unknown mechanisms) regain proliferative potential and give rise to clinically detectable tumor masses.
Proliferation at the primary tumor site is associated with metastasis formation in the regional lymph node, 32 but melanoma can recur much later (45 years) in patients with no/low proliferation in their primary tumors. 33 Even very late recurrences (410 years), observed in approximately 7% of melanoma patients, can be associated with negative sentinel lymph node biopsy, 34 suggesting that dissemination has occurred through the vascular system and that the disseminated cells have remained dormant for extended times. The mechanisms driving the switch between dormant state and metastasis development are not clear, but likely result from cues in the microenvironment. The clinical implication of the LRC phenotype is that if some cells are able to disseminate in the first phases of tumor growth, they will escape surgical excision, which is the predominant treatment for primary melanomas. Therefore, separate strategies are needed to target these cells for achieving a complete eradication of the tumor.
Using the unbiased approach of directly comparing proteomes from total extracts of matched LRC and non-LRC, we identified SerpinE2, BMP1 and PDGFRL as potential markers for melanoma LRC (Figure 3; Supplementary Figure 6 ; Supplementary Tables 1-4) . As PDGFRL has been poorly studied and no antibodies were available, this protein was not investigated further. BMP1 is a member of the bone morphogenic protein family that is normally secreted during cartilage development and has a major role in proto-collagen and proto-laminin 5 cleavage. [35] [36] [37] In cancer development and progression, BMP1 is associated with metastasis in non-small cell lung cancer 38 and structurally analogous members are associated with colon cancer progression, 39 likely via Src activation, 40 but in general the role of BMP1 in cancer is not well defined.
SerpinE2 is secreted by nerve and vascular cells in physiological conditions and by platelets upon activation at tissue injury sites. 41 It has anti-serine protease activity to many proteases but its main function is to regulate the plasminogen-plasmin axis, functioning as a plasminogen activator inhibitor. [42] [43] [44] SerpinE2 inhibits its targets by the standard serpin inhibitory mechanism, involving protease binding and cleavage of the reactive center loop, triggering a large conformational change to the serpin molecule trapping the targeted protease in a covalent inactive complex. 45, 46 In mammalian cells, serpin-protease complexes bind to members of the low-density lipoprotein receptor family such as low-density lipoprotein receptor-related protein 1 (alpha2-macroglobulin receptor or CD91), triggering a variety of signaling events. 47 SerpinE2 has a pro-invasive role in cancer. 48 Earlier reports found that SerpinE2 promotes invasion of pancreatic, testicular, mammary, prostate, and lung cancers and gliomas. [49] [50] [51] [52] [53] [54] [55] SerpinE2 is upregulated in epithelial cells after oncogenic activation 56 and during the progression from pre-neoplastic lesions to medulloblastoma. 57 SerpinE2 has not been studied in detail in melanoma, except a recent report associates SerpinE2 to melanoma invasiveness. 58 It is not clear how serpins and SerpinE2 contribute to metastasis formation; two recent reports suggest two different mechanisms of action. Serpins could shield metastatic cells from Fas-mediated killing activated by plasminogen-plasmin, providing a pro-metastatic advantage, 59 or serpins could act as anticoagulants at the vascular/extravascular interface in the tumor, increasing vascular leakiness favoring extravasation. 60 One possible scenario is that LRC, through active secretion of SerpinE2, could direct modulate non-LRC properties, making them more invasive similarly to report in a Zebrafish melanoma model. 61 Our data confirm the findings in the fish models that non-LRC express SerpinE2 receptors (Supplementary Figure 5B ) and that recombinant SerpinE2 in culture media can directly stimulate non-LRC invasion (Figure 4a ; Supplementary Figure 7A ). We can also postulate that SerpinE2 contributes to both invasion and survival of LRC. For example, several SerpinE2-associated processes may contribute to LRC extravasation, invasion, and survival in the newly-seeded tissue: cell cycle exit promotion and integrin inactivation achieved in an urokinase Plasminogen activator receptor-dependent manner, 62, 63 induction of metalloproteinase release, 53, 55 or apoptosis prevention. 64 We directly linked SerpinE2 to melanoma invasiveness by first showing that SerpinE2-positive cells have disseminated to mouse lungs, liver and lymph nodes (Figure 3d; Supplementary Figures  6B, C) , and then showing that exogenous SerpinE2 stimulates invasion of non-LRC and its neutralization prevents invasion by (Figure 4; Supplementary Figure 7) . Moreover, our data confirm that SerpinE2 is exclusively linked to melanoma cells' invasive capacities. SerpinE2 does not control melanoma cell proliferation, since its abrogation does not change proliferation dynamics or cell viability ( Supplementary Figure 9 ). Furthermore, our data show that there is no direct correlation with MITF expression (Supplementary Figure 6F) or Ki67 (Supplementary Figure 4C ). In particular in skin reconstruct, SerpinE2-positive cells were either positive or negative for Ki67. It appears that scattered SerpinE2+ cells are generally negative for Ki67 ( Supplementary  Figure 4C , top lane) while SerpinE2+ cells found in clusters stain positive for Ki67 ( Supplementary Figure 4C , bottom lane). In some areas it is also possible the co-existence of SerpinE2-positive cells that are either positive or negative for Ki67 ( Supplementary  Figure 4C , middle panel). Unfortunately, there are technical limitations that do not allow live imaging of single-cell migration nor can we detect co-expression of SerpinE2 and PKH26 in vivo.
Our in vitro observations (Figures 4 and 5) were confirmed in patients' tissues (Figures 5c-e) , where SerpinE2 expression correlated with highly malignant lesions. Normal tissue surrounding melanoma lesions is completely negative for SerpinE2. In VGP primary melanoma, two populations of cells co-exist, those that are high-and low-expressing the protein. Vertical growth is the first invasive step of melanomas, in which both invasive and not invasive cells are present within the tumor mass. Increased expression of SerpinE2 could favor the selection of invasive cells to develop a metastatic mass, that is homogenously highly positive for SerpinE2 (Figure 5f ). Once disseminated, LRC regain proliferation capacity as demonstrated in vitro and in vivo ( Supplementary  Figures 3A, 4B and C) and can regenerate the tumor mass. Our data are in line with clinical reports that describe increased SerpinE2 in aggressive stages of gastric, 65 colon 66 and oral squamous cell carcinomas. 67 To complete our study on SerpinE2 role in melanoma, we analyzed SerpinE2 expression in tissue of patients using publicly available data sets. When the TCGA data set was analyzed (469 melanoma samples), we found SerpinE2 mRNA expression upregulated in 6% of patients. These patients show better survival, compared to patients with unvariated expression of SerpinE2. The differences between relative expression levels of SerpinE2 and survival may depend on the type of treatment patients received subsequently to tissue removal. Expression may also depend on size of lesion, location and presence of host cells. In a smaller set of 38 patients with mostly stage 3 melanoma (GSE19234), SerpinE2 expression is associated with poor survival, when compared to patients with relatively low expression of SerpinE2. These descrepancies suggest the need for further correlative studies on SerpinE2 expression with survival, particularly in VGP primary melanomas and biologically early (i.e., regional lymph node) metastases.
In summary, we have shown that melanoma slow-cycling cells (LRC) exist in vitro and in vivo. They disseminate early during tumor growth and are able to efficiently give rise to metastatic lesions at distant sites. We identify a new role for SerpinE2 as responsible for melanoma LRC invasiveness, by what appears to directly involve its anti-proteolytic activity; therefore, a potential new target to prevent or limit melanomas' early dissemination. We summarized our hypothesis in Supplementary Figure 10 . We believe that melanoma slow-cycling cells are primed to invade due to their transcriptional program. Among LRC, SerpinE2 high cells are favored in the dissemination process and are selected during organ colonization. Once disseminated, LRC-SerpinE2 high cells proliferate and generate non-LRC without losing SerpinE2 expression. Thus, metastases express almost homogenously high SerpinE2. Since SerpinE2 is expressed exclusively by melanoma cells, it is potentially a useful tool to detect isolated malignant cells disseminated in normal organ parenchyma.
MATERIALS AND METHODS
LRC detection
Melanoma cells were stained with CellTrace Violet cell proliferation kit or with PHK26 Red Fluorescent Cell Linker mini-kit (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's protocol. Fluorescence dilution was measured at indicated time points by flow cytometry (LSRII, Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using FlowJo Software v10.0 (FlowJo, LLC, Ashland, OR, USA) after normalization on unstained cells. Labeled cells were grown in culture in melanoma media (MCDB154 +L-15+2%FBS) for 10-14 days, harvested and stained with DAPI before sorting with MoFlo ® Astrios™ (Beckman Coulter, Brea, CA, USA).
In vivo studies
Melanoma cells were stained with PHK26 and 1 × 10 6 cells/mouse were injected subcutaneously with Matrigel in 1:1 ratio in SHO mice. Tumor growth was measured once to twice a week with manual caliper and mice were imaged by IVIS200 (PerkinElmer) once a week. Dorsal, ventral and lateral scanning was performed. Fluorescent signal was quantified through Living Image 4.3.1 (PerkinElmer), after subtraction of the background. Because IVIS allows in vivo fluorescence detection below 1 cm depth, we also harvested organs at the end of the experiment for additional LRC detection through imaging and flow cytometry.
Proteomic analyses
Proteins at 50 μg/sample were used for proteomic analyses. Proteins were obtained as described. 68, 69 Filter-aided sample preparation was performed as described. 70, 71 Eluates were vacuum-concentrated and reconstituted in 2 mM ammonia formate buffer and subjected to Tandem Mass Tag™ system (Thermo Fisher Scientific, Waltham, MA, USA) labeling according to manufacturer's instructions. Two-dimensional liquid chromatography was performed by reversed-phase chromatography at high and low pH as described. 72 Mass spectrometry was performed on a hybrid linear trap quadruple Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) using Xcalibur software 2.1.0 (Thermo Fisher Scientific) coupled to an Agilent 1200 HPLC nanoflow system (Proxeon, Odense, Denmark). MS data files were processed with MSConvert (ProteoWizard Library v2.1.2708) and converted into Mascot (MatrixScience, London, UK) files. Peak lists were searched against the human SwissProt database version v2013.01_ 20130110 73 with the search engines Mascot (v2.3.02) and Phenyx (v2.5.14, GeneBio, Geneva, Switzerland). 74 Proteins with ⩾ 2 unique peptides above a score T1, or with a single peptide above a score T2, were selected as unambiguous identifications. Additional peptides for these validated proteins with score 4T3 were also accepted. For Mascot and Phenyx, T1, T2 and T3 were equal to 16, 40, 10 and 5.5, 9.5, 3.5, respectively (P-value o 10 -3 ). Following the selection criteria, proteins were grouped based on shared peptides, and only the group reporters are considered in the final output of identified proteins. Peptide-spectrum match conflicts between Mascot and Phenyx were discarded. The entire procedure was repeated against a reversed database to assess the protein group false discovery rate (FDR). Peptide and protein group identifications were o 0.1 and o1% FDR, respectively. The R software package Isobar 75 was used to calculate protein ratios and assess their significance. Protein ratios were calculated based on unique peptides. Proteins were denoted as significantly regulated when their ratio P-value was o 0.05, and the ratio itself was 42.5 times the median absolute deviation from the median.
Immunohistochemistry
Fifteen radial growth phase melanomas, 15 metastatic melanomas, and 10 nevi were analyzed. Formalin-fixed, paraffin-embedded tissue sections (1-2 μm) were stained with mouse anti-human SerpinE2 antibody (Origene) followed by polymer staining and Fast-Red for 7 min at RT. Nuclei were counterstained with Hematoxylin for 5 min at RT. Antigen retrieval was achieved at 99°C for 20 min with ER2 solution (Leica Microsystems, Inc., Buffalo Grove, IL, USA).
Western blotting
For culture supernatant analyses, 2E6 cells were plated in a 6 cm-diameter culture dish for 48 h with 8 ml of culture media. Culture media were harvested, filtered through Millex-GP Syringe-driven Filter Unit (EMD Millipore, part of Merck KGaA, Darmstadt, Germany) and 40 μl of supernatant/sample were used. Samples were boiled 10 min in NuPAGE LDS sample buffer (Thermo Fisher Scientific), loaded on 10% gels, transferred onto nitrocellulose filters and immunoblotted with mouse anti-human SerpinE2 antibody (R&D), diluted 1:500. Anti-mouse secondary antibody was from IRDye (LI-COR Biosciences, Lincoln, NE, USA) and was used at 1:10 000 dilution and membranes were analyzed by Odyssey (LI-COR Biosciences). Densitometry analysis was performed using Odyssey and data were normalized on the total protein detected after Ponceau's staining.
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